"This research was a tour de force," says Martin Hetzer, Salk's Chief Science Officer, and the study's senior author. "Tobias Franks, my postdoctoral researcher at the time and the paper's first author, used an approach that combined genomics, proteomics, and cell biology. This model wasn't easy to study, and he developed some very clever techniques in the lab to answer these questions."
‘Nup98 can act through a link with a protein complex called Wdr82-Set1/COMPASS, which is part of the cell's epigenetic machinery.’
For years, Hetzer's lab has focused on a class of proteins called nucleoporins (nups for short), which are part of the nuclear pore complex. This complex regulates traffic between the nucleus of the cell, where the genetic material is located, and the cytoplasm, which contains other cellular structures. There are about 30 proteins in the nucleoporin family, and they carry out a number of different functions in addition to forming the nuclear pore. Several of them are known to act as transcription factors: This means they help to regulate when and how genes get translated into proteins.
The finding that nup98 has this additional function was not entirely unexpected. Earlier research from Hetzer's lab had found that it plays a role in gene regulation in other cell types. But the team didn't know about its function in hematopoietic (blood) cells.
Also, until now the mechanism of how nup98 regulates transcription was not known. The investigators found that it acts through a link with a protein complex called Wdr82-Set1/COMPASS, which is part of the cell's epigenetic machinery. "This epigenetic process helps to control when genes are transcribed into proteins and when transcription is blocked," says Hetzer, who also holds the Jesse and Caryl Phillips Foundation Chair.
Another thing that was different about this study is that it was done in mouse cells rather than simpler model organisms like yeast and fruit flies. "This is the first mechanistic insight of how one of these nup proteins works in mammals," Hetzer adds. "We have only touched the surface here in uncovering how this evolutionarily conserved mechanism works in mammalian cells." Future work in his lab will extend the study of nup98 to primates and humans.
While Hetzer has no immediate plans to pursue their findings as an avenue for developing leukemia drugs, he says it's likely that others may pick up on this aspect of the research. Disruption of the cell differentiation process that contributes to leukemia results from a single gene fusion, when two parts of chromosomes that are not meant to act on each other become linked. He says that cancers driven by a single genetic change like this have proven easier to block with drugs than cancer driven by multiple genetic alterations.